Literature DB >> 26949186

Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody.

Mattia Bonsignori1, Tongqing Zhou2, Zizhang Sheng3, Lei Chen2, Feng Gao1, M Gordon Joyce2, Gabriel Ozorowski4, Gwo-Yu Chuang2, Chaim A Schramm3, Kevin Wiehe1, S Munir Alam1, Todd Bradley5, Morgan A Gladden5, Kwan-Ki Hwang5, Sheelah Iyengar5, Amit Kumar5, Xiaozhi Lu5, Kan Luo5, Michael C Mangiapani5, Robert J Parks5, Hongshuo Song5, Priyamvada Acharya2, Robert T Bailer2, Allen Cao2, Aliaksandr Druz2, Ivelin S Georgiev6, Young D Kwon2, Mark K Louder2, Baoshan Zhang2, Anqi Zheng2, Brenna J Hill2, Rui Kong2, Cinque Soto2, James C Mullikin7, Daniel C Douek2, David C Montefiori8, Michael A Moody9, George M Shaw10, Beatrice H Hahn10, Garnett Kelsoe11, Peter T Hraber12, Bette T Korber12, Scott D Boyd13, Andrew Z Fire13, Thomas B Kepler14, Lawrence Shapiro15, Andrew B Ward4, John R Mascola2, Hua-Xin Liao1, Peter D Kwong16, Barton F Haynes17.   

Abstract

Antibodies with ontogenies from VH1-2 or VH1-46-germline genes dominate the broadly neutralizing response against the CD4-binding site (CD4bs) on HIV-1. Here, we define with longitudinal sampling from time-of-infection the development of a VH1-46-derived antibody lineage that matured to neutralize 90% of HIV-1 isolates. Structures of lineage antibodies CH235 (week 41 from time-of-infection, 18% breadth), CH235.9 (week 152, 77%), and CH235.12 (week 323, 90%) demonstrated the maturing epitope to focus on the conformationally invariant portion of the CD4bs. Similarities between CH235 lineage and five unrelated CD4bs lineages in epitope focusing, length-of-time to develop breadth, and extraordinary level of somatic hypermutation suggested commonalities in maturation among all CD4bs antibodies. Fortunately, the required CH235-lineage hypermutation appeared substantially guided by the intrinsic mutability of the VH1-46 gene, which closely resembled VH1-2. We integrated our CH235-lineage findings with a second broadly neutralizing lineage and HIV-1 co-evolution to suggest a vaccination strategy for inducing both lineages.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26949186      PMCID: PMC4826291          DOI: 10.1016/j.cell.2016.02.022

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  42 in total

1.  Satisfying hydrogen bonding potential in proteins.

Authors:  I K McDonald; J M Thornton
Journal:  J Mol Biol       Date:  1994-05-20       Impact factor: 5.469

2.  Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Authors:  Florian Klein; Ron Diskin; Johannes F Scheid; Christian Gaebler; Hugo Mouquet; Ivelin S Georgiev; Marie Pancera; Tongqing Zhou; Reha-Baris Incesu; Brooks Zhongzheng Fu; Priyanthi N P Gnanapragasam; Thiago Y Oliveira; Michael S Seaman; Peter D Kwong; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

3.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

4.  Polyreactivity and autoreactivity among HIV-1 antibodies.

Authors:  Mengfei Liu; Guang Yang; Kevin Wiehe; Nathan I Nicely; Nathan A Vandergrift; Wes Rountree; Mattia Bonsignori; S Munir Alam; Jingyun Gao; Barton F Haynes; Garnett Kelsoe
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

5.  HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.

Authors:  Joseph G Jardine; Takayuki Ota; Devin Sok; Matthias Pauthner; Daniel W Kulp; Oleksandr Kalyuzhniy; Patrick D Skog; Theresa C Thinnes; Deepika Bhullar; Bryan Briney; Sergey Menis; Meaghan Jones; Mike Kubitz; Skye Spencer; Yumiko Adachi; Dennis R Burton; William R Schief; David Nemazee
Journal:  Science       Date:  2015-06-18       Impact factor: 47.728

Review 6.  Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

Authors:  Laurent Verkoczy; Garnett Kelsoe; M Anthony Moody; Barton F Haynes
Journal:  Curr Opin Immunol       Date:  2011-04-27       Impact factor: 7.486

7.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

8.  Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.

Authors:  Peter Hraber; Michael S Seaman; Robert T Bailer; John R Mascola; David C Montefiori; Bette T Korber
Journal:  AIDS       Date:  2014-01-14       Impact factor: 4.177

9.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

10.  Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors.

Authors:  Thomas B Kepler
Journal:  F1000Res       Date:  2013-04-03
View more
  164 in total

1.  IgA Summons IgG to Take a Hit at HIV-1.

Authors:  Giuliana Magri; Andrea Cerutti
Journal:  Cell Host Microbe       Date:  2020-06-10       Impact factor: 21.023

Review 2.  What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Is Affinity Maturation a Self-Defeating Process for Eliciting Broad Protection?

Authors:  Christopher T Stamper; Patrick C Wilson
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

3.  SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Philippe Colin; Jonathan L Torres; Anila Yasmeen; Wen-Hsin Lee; Albert Cupo; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

Review 4.  What Are the Most Powerful Immunogen Design Vaccine Strategies? A Structural Biologist's Perspective.

Authors:  Peter D Kwong
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

5.  Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.

Authors:  Ema T Crooks; Keiko Osawa; Tommy Tong; Samantha L Grimley; Yang D Dai; Robert G Whalen; Daniel W Kulp; Sergey Menis; William R Schief; James M Binley
Journal:  Virology       Date:  2017-03-06       Impact factor: 3.616

Review 6.  How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.

Authors:  Marie Pancera; Anita Changela; Peter D Kwong
Journal:  Curr Opin HIV AIDS       Date:  2017-05       Impact factor: 4.283

7.  SIV infection duration largely determines broadening of neutralizing antibody response in macaques.

Authors:  Fan Wu; Ilnour Ourmanov; Andrea Kirmaier; Sivan Leviyang; Celia LaBranche; Jinghe Huang; Sonya Whitted; Kenta Matsuda; David Montefiori; Vanessa M Hirsch
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

8.  Optimizing immunization protocols to elicit broadly neutralizing antibodies.

Authors:  Kayla G Sprenger; Joy E Louveau; Pranav M Murugan; Arup K Chakraborty
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-03       Impact factor: 11.205

9.  Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection.

Authors:  Bongiwe Ndlovu; Kamini Gounder; Daniel Muema; Nagarajan Raju; Tandile Hermanus; Qiniso Mthethwa; Kim Robertson; Bruce D Walker; Ivelin S Georgiev; Lynn Morris; Penny L Moore; Thumbi Ndung'u
Journal:  Virology       Date:  2020-03-25       Impact factor: 3.616

Review 10.  Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.

Authors:  Julia L Hurwitz; Mattia Bonsignori
Journal:  Viral Immunol       Date:  2018-01-09       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.